Antibody response to enterotoxigenic of Filipino colorectal cancer patients.

Background: Several species of the gut microbiota have been implicated in colorectal cancer (CRC) development. The anaerobic bacterium enterotoxigenic (ETBF), has been identified to produce fragilysin, a toxin known to cleave E-cadherin, thereby leading to carcinogenesis.

Objective: To determine the antibody response of CRC patients against ETBF to ascertain whether significant difference exists or whether antibody response is related to tumor grade and tumor stage.

antibody response of colorectal cancer patients versus clinically healthy individuals.

Dysbiosis, defined as an imbalance in the gut microbiota caused by too few beneficial bacteria and an overgrowth of bad bacteria, yeast, and/or parasites, is now being associated with several diseases, including the development of colorectal carcinoma (CRC). In this study, the potential association of (formerly ) with CRC was investigated. Plasma samples obtained from preoperative histologically confirmed CRC patients (=39) and their age- and sex-matched clinically healthy controls (=39) were analyzed for antibodies to toxin B of (anti-tcdB) by enzyme-linked immunosorbent assay (ELISA).